comms@paragonbiosci.com

56 items

March 1, 2023

Emalex Biosciences Announces First Patient Dosed in Phase 3 Trial of Ecopipam for Tourette Syndrome
– Enrolled patients will receive medication for [...]
February 21, 2023

Harmony Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
WAKIX® (pitolisant) Net Revenue Increased ~41% Year-over-Year [...]
January 12, 2023

Evozyne Creates AI Model with NVIDIA for Novel Protein Design, Expected to Accelerate Drug Development
– New AI model, co-developed by Evozyne [...]
January 11, 2023

Emalex Biosciences Publishes Phase 2b Results for Tourette Syndrome Candidate in Pediatrics
– Study data shows investigational new drug, [...]
January 11, 2023

Veteran Technology Executive Mike Gamson Named Evozyne CEO
– Gamson to set commercial direction, strengthen [...]
November 3, 2022

Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndrome
– Clinical stage biopharmaceutical company completes upsized, [...]
June 24, 2022

Outstanding First Half for Paragon and its Portfolio Companies
Paragon and its portfolio companies continue to [...]
May 25, 2022

Castle Creek Biosciences Raises $112.8 Million to Advance Novel Gene Therapies and Expand Pipeline
– Funding expected to provide sufficient capital [...]

Previous 123 Next